229 related articles for article (PubMed ID: 24081805)
1. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
[TBL] [Abstract][Full Text] [Related]
2. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
4. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
5. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
6. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
[TBL] [Abstract][Full Text] [Related]
8. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A; Karadimou A; Lampaki S; Lainakis G; Malettou L; Timotheadou E; Papazisis K; Andreadis C; Kontovinis L; Anastasiou I; Stravodimos K; Xanthakis I; Skolarikos A; Christodoulou C; Syrigos K; Papandreou C; Razi E; Dafni U; Fountzilas G; Dimopoulos MA
BMC Cancer; 2010 Feb; 10():45. PubMed ID: 20163744
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
Sella A; Michaelson MD; Matczak E; Simantov R; Lin X; Figlin RA
Clin Genitourin Cancer; 2017 Apr; 15(2):291-299.e1. PubMed ID: 27638198
[TBL] [Abstract][Full Text] [Related]
14. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Matsubara N; Mukai H; Naito Y; Itoh K; Komai Y; Sakai Y
Urology; 2013 Jul; 82(1):118-23. PubMed ID: 23806397
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
16. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
17. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J
BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK
J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]